Hemotune raises €4.7M Series A round
12 August 2020· Zurich, Switzerland· health, medtech, nanotechnology, biotech, magnetic_separation, b2b, software_hardware
The funding will go to accelerating preclinical development of Hemotune's device.
Investors
LeadOCCIDENT
Also participating
Zürcher KantonalbankGreen Cross Medical Science
About Hemotune
Stage
Series B
Headquarters
Zurich, Switzerland
Founded
2017
Team Size
21–50
Sectors
healthmedtechnanotechnologybiotechmagnetic_separationb2bsoftware_hardware